# Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

**Authors:** Maryam Zanjirband, Nicola Curtin, Richard J. Edmondson, John Lunec

PMC · DOI: 10.18632/oncotarget.28523 · Oncotarget · 2024-02-22

## Full-text entities

- **Genes:** MDM2 (MDM2 proto-oncogene) [NCBI Gene 4193] {aka ACTFS, HDMX, LSKB, hdm2}
- **Diseases:** ovarian cancer (MESH:D010051)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10883681/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10883681/full.md

---
Source: https://tomesphere.com/paper/PMC10883681